Aytu BioPharma (AYTU) Projected to Post Earnings on Wednesday

Aytu BioPharma (NASDAQ:AYTU) is expected to release its Q2 2026 results before the market opens on Wednesday, February 11th. Analysts expect Aytu BioPharma to post earnings of ($0.26) per share for the quarter. Interested persons may review the information on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Tuesday, February 3, 2026 at 4:30 PM ET.

Aytu BioPharma (NASDAQ:AYTU) last released its quarterly earnings data on Tuesday, February 3rd. The company reported ($1.05) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.79). Aytu BioPharma had a negative net margin of 20.52% and a positive return on equity of 17.86%. The firm had revenue of $15.17 million during the quarter.

Aytu BioPharma Stock Down 3.3%

NASDAQ:AYTU opened at $2.62 on Wednesday. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.23 and a quick ratio of 1.08. Aytu BioPharma has a 1-year low of $0.95 and a 1-year high of $3.07. The company has a 50-day moving average of $2.51 and a 200 day moving average of $2.35. The firm has a market cap of $26.70 million, a PE ratio of -0.86 and a beta of 0.37.

Hedge Funds Weigh In On Aytu BioPharma

A hedge fund recently raised its stake in Aytu BioPharma stock. Two Sigma Investments LP raised its holdings in shares of Aytu BioPharma Inc. (NASDAQ:AYTU) by 96.2% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 68,736 shares of the company’s stock after purchasing an additional 33,701 shares during the period. Two Sigma Investments LP owned 0.67% of Aytu BioPharma worth $129,000 at the end of the most recent quarter. Institutional investors and hedge funds own 33.49% of the company’s stock.

Trending Headlines about Aytu BioPharma

Here are the key news stories impacting Aytu BioPharma this week:

• Positive Sentiment: Company launched EXXUA (gepirone) extended‑release tablets in December 2025 as the centerpiece of its push into the >$22B U.S. major depressive disorder market — a long‑term revenue driver if uptake accelerates. Aytu Launch/Results Release
• Positive Sentiment: Company reported roughly $15.2M in Q2 net revenue (reported as a beat of revenue estimates) and closed the quarter with ~$30.0M in cash — provides runway for EXXUA commercialization investments. Revenue Beat/Details
• Neutral Sentiment: Adjusted EBITDA was $(0.8)M for the quarter after EXXUA launch investments — indicates management is investing in rollout but not yet profitable on an adjusted basis. Adjusted EBITDA/Release
• Neutral Sentiment: Earnings call/transcript available — listen for management’s commercial cadence, early EXXUA prescriptions, pricing, and FY guidance updates (these items will drive near‑term sentiment). Earnings Call Transcript Alternate Transcript
• Negative Sentiment: Q2 GAAP EPS was a large miss at ($1.05) vs. consensus ($0.26) — the magnitude of the loss likely triggered selling and increased downside risk until clearer EXXUA commercial traction appears. EPS Miss Coverage
• Negative Sentiment: Zacks recently placed AYTU on its Zacks Rank #5 (Strong Sell) list — a headline that can amplify selling pressure from momentum and quant-based funds. Zacks Rank

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on AYTU shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aytu BioPharma in a research report on Friday, January 9th. Zacks Research lowered Aytu BioPharma from a “hold” rating to a “strong sell” rating in a report on Friday, January 30th. Finally, Ascendiant Capital Markets increased their target price on Aytu BioPharma from $12.50 to $13.00 and gave the company a “buy” rating in a research report on Wednesday, December 10th. Three equities research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $9.33.

Aytu BioPharma Company Profile

Aytu BioPharma, Inc is a specialty pharmaceutical company focused on the development, licensing and commercialization of novel therapeutics to address underserved medical needs. Headquartered in Englewood, Colorado, Aytu pursues a strategy of acquiring late-stage or approved products in areas such as urology, endocrinology, women’s health, pediatric care and supportive therapies. The company leverages in-house commercialization capabilities and targeted business development to build a diversified portfolio of prescription medicines and diagnostics.

Aytu’s marketed portfolio includes Natesto, a nasal testosterone gel for treatment of male hypogonadism; ZolpiMist, a zolpidem tartrate lingual spray for the short-term treatment of insomnia; and Tuzistra XR, an extended-release cough syrup formulation indicated for relief of cough and upper respiratory symptoms.